SCHEMBL30891501

SCHEMBL30891501

C[C@@H]1O[C@@H](OCCNC(=O)CN(CC(=O)NCCCCCNC(=O)OCc2ccccc2)CC(=O)NCCO[C@H]2O[C@H](CO[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)[C@@H](O)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)[C@@H]2O)[C@@H](O)[C@H](O)[C@@H]1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP13 P45452 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ LGALS8 O00214 1/20 0.40
▸ MMP2 P08253 1/20 0.39
▸ MMP3 P08254 1/20 0.39
▸ MMP9 P14780 1/20 0.39
▸ MMP12 P39900 1/20 0.39
▸ FGF1 P05230 4/20 0.39
▸ VEGFA P15692 3/20 0.39
▸ FGF2 P09038 2/20 0.39
▸ HPSE Q9Y251 2/20 0.39
▸ CD209 Q9NNX6 2/20 0.39
▸ PRKCA P17252 3/20 0.38
▸ TACR1 P25103 1/20 0.38
▸ SELP P16109 1/20 0.37
▸ SLC6A2 P23975 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30891378 0.97 MMP13 (0.46) MMP13ALDH1A1CYP3A4ALOX15MAPK1
SCHEMBL30891306 0.93 MMP13 (0.47) MMP13LGALS8FGF1VEGFAFGF2
SCHEMBL29880337 0.89 MMP13 (0.46) MMP13LGALS8FGF1VEGFAFGF2
SCHEMBL30891312 0.89 MMP13 (0.46) MMP13LGALS8FGF1VEGFAFGF2
SCHEMBL30891369 0.89 MMP13 (0.46) MMP13LGALS8FGF1VEGFAFGF2
SCHEMBL30391867 0.88 LMNA (0.43) MMP13LGALS8
SCHEMBL30391571 0.88 MMP13 (0.44) MMP13ALDH1A1CYP3A4ALOX15MAPK1
SCHEMBL16644758 0.88 MMP13 (0.47) MMP13ALDH1A1CYP3A4ALOX15MAPK1
SCHEMBL15130853 0.88 MMP13 (0.47) MMP13LGALS8FGF1VEGFAFGF2
SCHEMBL30891291 0.87 MMP13 (0.44) MMP13LGALS8FGF1VEGFAFGF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260021190-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES MERCK SHARP & DOHME LLC (US) 2026-01-22 — — US disclosed
EP-4615487-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES Merck Sharp & Dohme LLC (US) 2025-09-17 — — EP disclosed
WO-2024102633-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES MERCK SHARP & DOHME LLC (US) 2024-05-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260021190-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES INSR, GPR119, GLP1R MMP13 1271/4885ALDH1A1 2398/4885CYP3A4 611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback